AR and neoplasm: In AR expressing prostate cancer cell lines, CWP232291 treatment significantly decreased the expression of the AR or AR splice variants (in LNCaP and VCaP cells, respectively), and anti-tumor activity was observed in four primary CRPC patient samples, including a docetaxel-resistant sample [230].